Tilt Investment Management Holdings PBC Sells 1,627 Shares of Boston Scientific Co. (NYSE:BSX)

Tilt Investment Management Holdings PBC decreased its position in shares of Boston Scientific Co. (NYSE:BSX) by 21.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,950 shares of the medical equipment provider’s stock after selling 1,627 shares during the quarter. Tilt Investment Management Holdings PBC’s holdings in Boston Scientific were worth $344,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of BSX. Bruce G. Allen Investments LLC bought a new stake in Boston Scientific during the 4th quarter valued at $28,000. Venturi Wealth Management LLC raised its holdings in shares of Boston Scientific by 58.0% in the 4th quarter. Venturi Wealth Management LLC now owns 586 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 215 shares during the last quarter. Coppell Advisory Solutions LLC bought a new position in Boston Scientific in the 2nd quarter valued at about $34,000. Motco boosted its stake in Boston Scientific by 136.3% during the 3rd quarter. Motco now owns 645 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 372 shares during the last quarter. Finally, Sunbelt Securities Inc. bought a new stake in Boston Scientific during the 1st quarter worth approximately $32,000. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Performance

Shares of BSX traded down $0.71 during trading hours on Thursday, hitting $67.25. The company’s stock had a trading volume of 3,918,760 shares, compared to its average volume of 6,340,353. The business has a 50 day simple moving average of $67.17 and a two-hundred day simple moving average of $59.68. Boston Scientific Co. has a 52-week low of $48.35 and a 52-week high of $69.21. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.32 and a quick ratio of 0.82. The company has a market cap of $98.66 billion, a price-to-earnings ratio of 63.51, a PEG ratio of 2.39 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, January 31st. The medical equipment provider reported $0.55 EPS for the quarter, topping the consensus estimate of $0.51 by $0.04. Boston Scientific had a net margin of 11.19% and a return on equity of 15.99%. The company had revenue of $3.73 billion during the quarter, compared to the consensus estimate of $3.59 billion. During the same period last year, the firm earned $0.45 EPS. On average, equities analysts expect that Boston Scientific Co. will post 2.25 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have weighed in on BSX. Mizuho upgraded Boston Scientific from a “neutral” rating to a “buy” rating and raised their price objective for the company from $65.00 to $80.00 in a research note on Thursday, February 1st. Raymond James boosted their price target on shares of Boston Scientific from $67.00 to $73.00 and gave the stock a “strong-buy” rating in a report on Thursday, February 1st. Truist Financial upped their price objective on shares of Boston Scientific from $59.00 to $66.00 and gave the stock a “buy” rating in a research report on Friday, December 22nd. TD Cowen lifted their target price on shares of Boston Scientific from $65.00 to $77.00 and gave the stock an “outperform” rating in a research report on Thursday, March 7th. Finally, Argus boosted their target price on Boston Scientific from $69.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Two investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $68.50.

Insider Transactions at Boston Scientific

In related news, EVP John Bradley Sorenson sold 16,351 shares of the business’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $69.30, for a total transaction of $1,133,124.30. Following the sale, the executive vice president now directly owns 50,638 shares in the company, valued at approximately $3,509,213.40. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $66.35, for a total value of $463,322.05. Following the sale, the executive vice president now owns 53,788 shares of the company’s stock, valued at approximately $3,568,833.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP John Bradley Sorenson sold 16,351 shares of Boston Scientific stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $69.30, for a total transaction of $1,133,124.30. Following the sale, the executive vice president now owns 50,638 shares of the company’s stock, valued at $3,509,213.40. The disclosure for this sale can be found here. Insiders sold 50,979 shares of company stock valued at $3,418,529 over the last three months. Company insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.